Thinking Engineering Prosta Spółka Akcyjna (KRS 0001137888, NIP 8172218456) is a Polish company, headquartered in Mielec, Podkarpackie voivodeship. THINKING ENGINEERING operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since November 13, 2024.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - Thinking Engineering
Identity
- Name
- Thinking Engineering Prosta Spółka Akcyjna
- Legal form
- PROSTA SPÓŁKA AKCYJNA
- Founded
- November 13, 2024
- Registry status as of
- December 3, 2025
- Latest entry
- October 18, 2025
- Founding act
- 25.10.2024 R., ZASTĘPCA NOTARIALNY ANNA WYTRYKOWSKA ZASTĘPCA NOTARIUSZA KINGI NAŁĘCZ, KANCELARIA NOTARIALNA W WARSZAWIE …
Articles of association history (1)
- October 25, 2024: 25.10.2024 R., ZASTĘPCA NOTARIALNY ANNA WYTRYKOWSKA ZASTĘPCA NOTARIUSZA KINGI NAŁĘCZ, KANCELARIA NOTARIALNA W WARSZAWIE PRZY ULICY BOYA-ŻELEŃSKIEGO 6/26, 24048/2024
Activities
Main activity
72.19.ZOther research and experimental development on natural sciences and engineering
Other activities
Address and contact
- Address
- UL. DWORCOWA, 4, 40, 39-300, MIELEC, POLSKA
- Voivodeship
- PODKARPACKIE
- District
- MIELECKI
- THINKING.ENGINEERING.PSA@GMAIL.COM
- Website
- Not disclosed in the registry
- E-delivery address
- Not disclosed in the registry
Operational status - Thinking Engineering
Founded
November 13, 2024
1 year in operation
Legal form
PROSTA SPÓŁKA AKCYJNA
Registry: RejP
Headquarters
MIELEC
PODKARPACKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
N/A
Shareholders
N/A
Board
4 people
Filed years
N/A
Registry entries
6
latest: October 18, 2025
No KPI data - financial statements and valuation are unavailable for this company.
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Thinking Engineering.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Captor Therapeutics: PLN 36 m of cash at 30 September 2025, runway to mid-2026 - clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
